Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Change in Inventory (2023 - 2025)

Historic Change in Inventory for Gyre Therapeutics (GYRE) over the last 3 years, with Q3 2025 value amounting to -$72000.0.

  • Gyre Therapeutics' Change in Inventory fell 11132.08% to -$72000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.5 million, marking a year-over-year increase of 3832.34%. This contributed to the annual value of $2.1 million for FY2024, which is 22243.85% up from last year.
  • Latest data reveals that Gyre Therapeutics reported Change in Inventory of -$72000.0 as of Q3 2025, which was down 11132.08% from $954000.0 recorded in Q2 2025.
  • Gyre Therapeutics' 5-year Change in Inventory high stood at $1.5 million for Q1 2025, and its period low was -$921000.0 during Q3 2023.
  • Moreover, its 3-year median value for Change in Inventory was $118000.0 (2024), whereas its average is $255909.1.
  • In the last 5 years, Gyre Therapeutics' Change in Inventory surged by 71452.99% in 2024 and then plummeted by 11132.08% in 2025.
  • Gyre Therapeutics' Change in Inventory (Quarter) stood at -$184000.0 in 2023, then skyrocketed by 164.13% to $118000.0 in 2024, then tumbled by 161.02% to -$72000.0 in 2025.
  • Its last three reported values are -$72000.0 in Q3 2025, $954000.0 for Q2 2025, and $1.5 million during Q1 2025.